Statin Induced Rhabdomyolysis with Non Oliguric Renal Failure: A Rare PresentationCorrespondence Address :
Dr. Tom Devasia,
Professor, Department of Cardiology, KMC Manipal University, Manipal-576104, Karnataka, India.
Statins are safe, well tolerated, efficient and time tested drugs for the management of hypercholesterolemia, and thus play a cardinal role in the management of patients with heart disease. Although safe in clinical practice, they are associated with adverse effects, clinically the most important and most severe being muscle related complications/myotoxicity. Rhabdomyolysis, though rare, is the most severe form of myotoxicity. The US Food and Drug Administration (USFDA) adverse event reporting system reports rate of statin induced rhabdomyolysis at 0.3-13.5 cases per 1,000,000 patients. We present a case of a 74-year-old male who presented with an acute coronary syndrome and was initiated on atorvastatin. However, patient developed atorvastatin induced rhabdomyolysis, with non oliguric renal failure, which subsequently improved on cessation of medication.
Atorvastatin, Hypercholesterolemia, Myotoxicity
Hashir Kareem, Devavrata Sahu, Mugula Sudhakar Rao, Tom Devasia. STATIN INDUCED RHABDOMYOLYSIS WITH NON OLIGURIC RENAL FAILURE:
A RARE PRESENTATION. Journal of Clinical and Diagnostic Research [serial online] 2017 March [cited: 2017 May 25 ]; 11:FD01-FD02. Available from
Date of Submission: Sep 29, 2016
Date of Peer Review: Oct 18, 2016
Date of Acceptance: Nov 08, 2016
Date of Publishing: Mar 01, 2017
Financial OR OTHER COMPETING INTERESTS: None.
- PubMed Central® (PMC)New
- Academic Search Complete Database
- Chemical Abstracts Service
- Directory of Open Access Journals (DOAJ)
- Embase & EMbiology
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Open J-Gate
- Popline (reproductive health literature)